Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1993 1
1996 1
2001 1
2002 1
2003 5
2004 3
2005 7
2006 12
2007 11
2008 6
2009 5
2010 8
2011 15
2012 27
2013 17
2014 23
2015 20
2016 28
2017 28
2018 30
2019 39
2020 86
2021 41
Text availability
Article attribute
Article type
Publication date

Search Results

360 results
Results by year
Filters applied: . Clear all
Page 1
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
Yu KH, Chen DY, Chen JH, Chen SY, Chen SM, Cheng TT, Hsieh SC, Hsieh TY, Hsu PF, Kuo CF, Kuo MC, Lam HC, Lee IT, Liang TH, Lin HY, Lin SC, Tsai WP, Tsay GJ, Wei JC, Yang CH, Tsai WC. Yu KH, et al. Among authors: wei jc. Int J Rheum Dis. 2018 Apr;21(4):772-787. doi: 10.1111/1756-185X.13266. Epub 2018 Jan 24. Int J Rheum Dis. 2018. PMID: 29363262 Review.
2018 APLAR axial spondyloarthritis treatment recommendations.
Tam LS, Wei JC, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, Dans L, Gu J, Hagino N, Kishimoto M, Reyes HM, Soroosh S, Stebbings S, Whittle S, Yeap SS, Lau CS. Tam LS, et al. Among authors: wei jc. Int J Rheum Dis. 2019 Mar;22(3):340-356. doi: 10.1111/1756-185X.13510. Epub 2019 Feb 28. Int J Rheum Dis. 2019. PMID: 30816645
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS; COAST-V and COAST-W Study Groups. Dougados M, et al. Among authors: wei jc. Ann Rheum Dis. 2020 Feb;79(2):176-185. doi: 10.1136/annrheumdis-2019-216118. Epub 2019 Nov 4. Ann Rheum Dis. 2020. PMID: 31685553 Free PMC article. Clinical Trial.
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song YW, Chen YH, Wei JC, Lee SH, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Akazawa R, Shiomi T, Yamada E. Tanaka Y, et al. Among authors: wei jc. Ann Rheum Dis. 2019 Oct;78(10):1320-1332. doi: 10.1136/annrheumdis-2019-215163. Epub 2019 Jul 26. Ann Rheum Dis. 2019. PMID: 31350270 Free PMC article. Clinical Trial.
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
Baraliakos X, Kivitz AJ, Deodhar AA, Braun J, Wei JC, Delicha EM, Talloczy Z, Porter B; MEASURE 1 Study Group. Baraliakos X, et al. Among authors: wei jc. Clin Exp Rheumatol. 2018 Jan-Feb;36(1):50-55. Epub 2017 May 15. Clin Exp Rheumatol. 2018. PMID: 28516874 Free article. Clinical Trial.
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ. Baeten D, et al. Among authors: wei jc. Ann Rheum Dis. 2018 Sep;77(9):1295-1302. doi: 10.1136/annrheumdis-2018-213328. Epub 2018 Jun 26. Ann Rheum Dis. 2018. PMID: 29945918 Free PMC article. Clinical Trial.
360 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page